Difference between revisions of "Cost effectiveness sensitivity"
From Testiwiki
m |
|||
| Line 2: | Line 2: | ||
| − | The effects of alternative vaccine compositions on the outcomes of the cost- | + | The effects of alternative vaccine compositions on the outcomes of the cost-effectiveness analysis were assessed. Five modifications for PCV10 and one for PCV13 were considered |
Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important. | Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important. | ||
| − | + | Three separate tables are displayed, each corresponding to a different quantity. | |
| − | PCV13adv.inIPD | + | The three quantities of interest are: |
| + | *PCV13adv.inIPD | ||
= (IPD under PCv10) - (IPD under PCV13) | = (IPD under PCv10) - (IPD under PCV13) | ||
| − | + | if positive, PCV13 saves IPD cases compared to PCV10 | |
| − | + | *price of PCV13 | |
| − | price of PCV13 | ||
= if PCV10 price set at 20e, what is the matching price for PCV13? | = if PCV10 price set at 20e, what is the matching price for PCV13? | ||
| − | + | *ICER | |
| − | ICER | ||
= incremental cost-effectiveness ratio for PCV10 at price 20e | = incremental cost-effectiveness ratio for PCV10 at price 20e | ||
| − | + | (in this table, this value is also average cost per QALY) | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | + | rows (vaccine composition PCV10 and its 5 modifications): | |
| + | [1] pcv10 | ||
| + | [2] pcv10 + 19A(direct effects only) | ||
| + | [3] pcv10 + 6A | ||
| + | [4] pcv10 + 19A(direct only) + 6A | ||
| + | [5] pcv10 + 19A(full) | ||
| + | [6] pcv10 + 19A(full) + 6A = PCV13 - 3 | ||
| + | columns (vaccine composition PCV13 with or without serotype 3): | ||
| + | [1] pcv13 - 3 (excluding serotype 3) | ||
| + | [2] pcv13 | ||
PCV13adv.inIPD price of PCV13 ICER | PCV13adv.inIPD price of PCV13 ICER | ||
Revision as of 19:12, 24 August 2014
This page is a encyclopedia article.
The page identifier is Op_en6838 |
|---|
| Moderator:Nobody (see all) Click here to sign up. |
|
Give your opinion to the peer rating of the content of this page. |
| Upload data
|
The effects of alternative vaccine compositions on the outcomes of the cost-effectiveness analysis were assessed. Five modifications for PCV10 and one for PCV13 were considered
Conclusion: The assumption about serotype 3 in PCV13 is crucial. In addition, assumptions about the role of 6A in PCV10 is important.
Three separate tables are displayed, each corresponding to a different quantity.
The three quantities of interest are:
*PCV13adv.inIPD
= (IPD under PCv10) - (IPD under PCV13)
if positive, PCV13 saves IPD cases compared to PCV10
*price of PCV13
= if PCV10 price set at 20e, what is the matching price for PCV13?
*ICER
= incremental cost-effectiveness ratio for PCV10 at price 20e
(in this table, this value is also average cost per QALY)
rows (vaccine composition PCV10 and its 5 modifications): [1] pcv10 [2] pcv10 + 19A(direct effects only) [3] pcv10 + 6A [4] pcv10 + 19A(direct only) + 6A [5] pcv10 + 19A(full) [6] pcv10 + 19A(full) + 6A = PCV13 - 3 columns (vaccine composition PCV13 with or without serotype 3): [1] pcv13 - 3 (excluding serotype 3) [2] pcv13
PCV13adv.inIPD price of PCV13 ICER
============== ============== ===============
PCV13-3 PCV13 PCV13-3 PCV13 PCV13-3 PCV13
--- --- ------- ----- ----- ----
pcv10 12 150 18 38 8077 8077
pcv10+19Ad -2 134 17 37 7714 7714
pcv10+6A 50 188 25 55 13590 13590
pcv10+19Ad+6A 32 169 24 52 12724 12724
pcv10+19Af -31 105 15 32 6198 6199
pcv10+19Af+6A * 137 * 43 * 9672
----------------
(PCV10 price=20)
